WO2008008803A3 - Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells - Google Patents

Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells Download PDF

Info

Publication number
WO2008008803A3
WO2008008803A3 PCT/US2007/073199 US2007073199W WO2008008803A3 WO 2008008803 A3 WO2008008803 A3 WO 2008008803A3 US 2007073199 W US2007073199 W US 2007073199W WO 2008008803 A3 WO2008008803 A3 WO 2008008803A3
Authority
WO
WIPO (PCT)
Prior art keywords
target cells
clostridial
toxins
targeting activity
altered targeting
Prior art date
Application number
PCT/US2007/073199
Other languages
French (fr)
Other versions
WO2008008803A2 (en
Inventor
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Original Assignee
Allergan Inc
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Lance E Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A Gilmore, Shengwen Li, Kei Roger Aoki filed Critical Allergan Inc
Priority to CA002658260A priority Critical patent/CA2658260A1/en
Priority to JP2009519644A priority patent/JP2009543557A/en
Priority to AU2007272515A priority patent/AU2007272515B2/en
Priority to EP07812772A priority patent/EP2038298A2/en
Publication of WO2008008803A2 publication Critical patent/WO2008008803A2/en
Publication of WO2008008803A3 publication Critical patent/WO2008008803A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Abstract

The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
PCT/US2007/073199 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells WO2008008803A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002658260A CA2658260A1 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009519644A JP2009543557A (en) 2006-07-11 2007-07-11 Modified clostridial toxin with enhanced translocation ability and altered targeting activity against clostridial toxin target cells
AU2007272515A AU2007272515B2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP07812772A EP2038298A2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80706206P 2006-07-11 2006-07-11
US60/807,062 2006-07-11

Publications (2)

Publication Number Publication Date
WO2008008803A2 WO2008008803A2 (en) 2008-01-17
WO2008008803A3 true WO2008008803A3 (en) 2008-07-31

Family

ID=38924118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073199 WO2008008803A2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Country Status (6)

Country Link
US (1) US7993656B2 (en)
EP (1) EP2038298A2 (en)
JP (1) JP2009543557A (en)
AU (1) AU2007272515B2 (en)
CA (1) CA2658260A1 (en)
WO (1) WO2008008803A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US8039587B2 (en) 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
WO2008008082A2 (en) * 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CA2657521A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
KR101604515B1 (en) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 Immuno-Based Botulinum Toxin Serotype A Activity Assays
CN102356091A (en) 2008-03-14 2012-02-15 阿勒根公司 Immuno-based botulinum toxin serotype a activity assays
ES2614990T3 (en) * 2008-06-12 2017-06-02 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
SI2406371T1 (en) 2009-03-13 2018-10-30 Allergan, Inc. Cells useful for immuno-based botulinum toxin serotype a activity assays
DK3281953T3 (en) 2009-03-13 2020-01-20 Allergan Inc IMMUN-BASED REDIRECT ENDOPEPTIDASE ACTIVITY ASSAYS
WO2011020114A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
CA2771298A1 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
KR20140015129A (en) * 2009-08-14 2014-02-06 알러간, 인코포레이티드 Methods of treating cancer using growth factor retargeted endopeptidases
CA2771289A1 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
WO2011020117A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
MX2012006985A (en) 2009-12-16 2012-09-12 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain.
JP5956350B2 (en) 2010-01-25 2016-07-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Methods for intracellular conversion of single chain proteins to their two chain forms
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
JP5905446B2 (en) * 2010-03-24 2016-04-20 ライフネット ヘルス BMP-4 peptide and method of use
MX369263B (en) 2010-05-20 2019-11-04 Allergan Inc Degradable clostridial toxins.
WO2012051447A1 (en) 2010-10-14 2012-04-19 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US9764009B2 (en) 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
EP2793934B1 (en) * 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US10451621B2 (en) 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
RU2673910C2 (en) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Method of producing proteolytically processed polypeptide
EP2934571B1 (en) 2012-12-18 2018-05-30 Allergan, Inc. Prophylactic treatment of herpes recurrence
EP3760186A1 (en) 2014-04-30 2021-01-06 Allergan, Inc. Formulations of biologics for intravesical instillation
JP6585157B2 (en) 2014-07-31 2019-10-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Formulation of biologics for intravesical infusion
BR112018003794A2 (en) 2015-08-27 2018-09-25 Massachusetts Inst Technology pain treatment compositions and methods
US10369190B2 (en) 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
SG11202003671VA (en) 2018-01-29 2020-08-28 Ipsen Biopharm Ltd Non-neuronal snare-cleaving botulinum neurotoxins
CN112165955A (en) 2018-05-21 2021-01-01 益普生生物制药有限公司 Inhibiting allodynia caused by bone cancer
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
EP4313120A1 (en) 2021-03-30 2024-02-07 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
BR112023018473A2 (en) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN AND INFLAMMATORY DISORDERS
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome
CN116947982A (en) * 2023-07-12 2023-10-27 吉林大学 Three dominant epitope peptide sequences and application thereof in influenza virus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
WO2006027207A1 (en) * 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
DE69511860T2 (en) 1994-05-31 2000-02-10 Allergan Inc MODIFICATION OF CLOSTRIDIUM TOXINES AND THEIR USE AS TRANSPORT PROTEINS
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US7132259B1 (en) 1999-08-25 2006-11-07 Allergan, Inc. Activatable recombinant neurotoxins
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
AU2005279741B2 (en) * 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
PL1830872T3 (en) 2004-12-01 2011-09-30 Sec Dep For Health Fusion proteins
AU2005311098B2 (en) 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CA2657521A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
WO2006027207A1 (en) * 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALPERN J L ET AL: "Characterization of the receptor-binding domain of tetanus toxin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 268, no. 15, 25 May 1993 (1993-05-25), pages 11188 - 11192, XP002151795, ISSN: 0021-9258 *
HERREROS J ET AL: "C-TERMINAL HALF OF TETANUS TOXIN FRAGMENT C IS SUFFICIENT FOR NEURONAL BINDING AND INTERACTION WITH A PUTATIVE PROTEIN RECEPTOR", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 347, no. PART 1, 1 April 2001 (2001-04-01), pages 199 - 204, XP001010346, ISSN: 0264-6021 *
RUMMEL A ET AL: "The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 51, no. 3, 15 December 2003 (2003-12-15), pages 631 - 643, XP002363868, ISSN: 0950-382X *

Also Published As

Publication number Publication date
WO2008008803A2 (en) 2008-01-17
JP2009543557A (en) 2009-12-10
US20080241881A1 (en) 2008-10-02
EP2038298A2 (en) 2009-03-25
AU2007272515A1 (en) 2008-01-17
CA2658260A1 (en) 2008-01-17
US7993656B2 (en) 2011-08-09
AU2007272515B2 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
WO2008008803A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2006099590A3 (en) Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2008105901A3 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
ATE463506T1 (en) CLOSTRIDIAL TOXINS ACTIVATED WITH CLOSTRIDIAL TOXINS
MX369263B (en) Degradable clostridial toxins.
ATE416191T1 (en) DEGRADABLE CLOSTRIDIAL TOXINS
WO2006125000A3 (en) Method for the production of resveratrol in a recombinant oleaginous microorganism
WO2008073446A3 (en) Methods and systems related to transmission of nutraceutical associated information
WO2008053232A3 (en) Mycotoxin-reducing composition
WO2008054821A3 (en) Mutant hydrolase proteins with enhanced kinetics and functional expression
WO2010014632A3 (en) Methods and compositions for improving the production of products in microorganisms
JP2009508489A5 (en)
WO2009100102A3 (en) Ts23 alpha-amylase variants with altered properties
WO2007100922A3 (en) Methods of making polymeric articles and polymeric articles formed thereby
WO2007136815A3 (en) Tagged microorganisms and methods of tagging
WO2006102652A3 (en) Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
BRPI0922276A2 (en) "unnaturally occurring microbial organism, and method for producing isopropanol, 4-hydroxybutyrate, and 1,4-butanediol."
WO2008033830A3 (en) Complexity-aware encoding
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2010014631A3 (en) Methods and compositions for improving the production of products in microorganisms
WO2008061256A3 (en) Tracking usage of portable media device
WO2008080900A3 (en) Methionine synthases with reduced product inhibition
WO2010138393A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2006047404A3 (en) Methods for the production of food grade extracts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812772

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007272515

Country of ref document: AU

Ref document number: 2658260

Country of ref document: CA

Ref document number: 2007812772

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009519644

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007272515

Country of ref document: AU

Date of ref document: 20070711

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0715453

Country of ref document: BR

Free format text: APRESENTE FOLHAS DO RELATORIO DESCRITIVO E DO DESENHO ADAPTADOS AO AN NO127/1997.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0715453

Country of ref document: BR

Free format text: PEDIDO RETIRADO POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI 2200 DE 05/03/2013.